DE69304895D1 - Elimination of multi-drug resistance by tetraarylethylenes - Google Patents

Elimination of multi-drug resistance by tetraarylethylenes

Info

Publication number
DE69304895D1
DE69304895D1 DE69304895T DE69304895T DE69304895D1 DE 69304895 D1 DE69304895 D1 DE 69304895D1 DE 69304895 T DE69304895 T DE 69304895T DE 69304895 T DE69304895 T DE 69304895T DE 69304895 D1 DE69304895 D1 DE 69304895D1
Authority
DE
Germany
Prior art keywords
tetraarylethylenes
drug resistance
elimination
certain
tumors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69304895T
Other languages
German (de)
Other versions
DE69304895T2 (en
Inventor
Sai Sunkara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Publication of DE69304895D1 publication Critical patent/DE69304895D1/en
Application granted granted Critical
Publication of DE69304895T2 publication Critical patent/DE69304895T2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Certain tetraarylethylenes reverse drug resistance in multi-drug resistant tumors. These compounds apparently function by inhibiting a p-glycoprotein pump which becomes activated in late stage tumor development and which is inherently present in tumors from certain origins.
DE69304895T 1992-02-06 1993-01-11 Elimination of multi-drug resistance by tetraarylethylenes Expired - Fee Related DE69304895T2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83254192A 1992-02-06 1992-02-06
PCT/US1993/000190 WO1993015733A1 (en) 1992-02-06 1993-01-11 Reversal of multi-drug resistance by tetraarylethylenes

Publications (2)

Publication Number Publication Date
DE69304895D1 true DE69304895D1 (en) 1996-10-24
DE69304895T2 DE69304895T2 (en) 1997-02-06

Family

ID=25261952

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69304895T Expired - Fee Related DE69304895T2 (en) 1992-02-06 1993-01-11 Elimination of multi-drug resistance by tetraarylethylenes

Country Status (19)

Country Link
US (2) US5523304A (en)
EP (1) EP0624090B1 (en)
JP (1) JPH07503728A (en)
KR (1) KR950700061A (en)
AT (1) ATE142879T1 (en)
AU (1) AU668910B2 (en)
CA (1) CA2129143C (en)
DE (1) DE69304895T2 (en)
DK (1) DK0624090T3 (en)
ES (1) ES2094525T3 (en)
GR (1) GR3021811T3 (en)
HU (1) HUT75163A (en)
IL (1) IL104599A (en)
MX (1) MX9300578A (en)
NO (1) NO942918L (en)
NZ (1) NZ246818A (en)
TW (1) TW226330B (en)
WO (1) WO1993015733A1 (en)
ZA (1) ZA93690B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996006604A2 (en) 1994-08-31 1996-03-07 Eli Lilly And Company Methods for identifying and treating resistant tumors
JP2000512997A (en) * 1996-06-17 2000-10-03 イーライ・リリー・アンド・カンパニー Drug resistance and multidrug resistance modulators
US6162616A (en) * 1997-04-16 2000-12-19 Millennium Pharmaceuticals, Inc. Multidrug resistance-associated polypeptide
US5776939A (en) * 1997-06-12 1998-07-07 Eli Lilly And Company Drug resistance and multidrug resistance modulators
AU6366000A (en) * 1999-07-23 2001-02-13 Colorado State University Research Foundation Multidrug resistance pump inhibitors and uses thereof
US6376514B1 (en) 2000-10-17 2002-04-23 The Procter & Gamble Co. Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof
US6693099B2 (en) 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
FR2906533B1 (en) * 2006-09-28 2013-02-22 Pf Medicament METHOD FOR GENERATING ACTIVE ANTIBODIES AGAINST A RESISTANCE ANTIGEN, ANTIBODIES OBTAINED THEREBY AND USES THEREOF
CN111909114A (en) * 2015-06-24 2020-11-10 香港科技大学 AIE luminophores for visualization and treatment of cancer
US10729669B2 (en) 2015-07-28 2020-08-04 University Of Iowa Research Foundation Compositions and methods for treating cancer
US9980951B2 (en) * 2015-12-17 2018-05-29 University Of Iowa Research Foundation Image guided therapy for cancer
AU2017281940A1 (en) 2016-06-24 2019-01-24 University Of Iowa Research Foundation Compositions and methods of treating melanoma
US11529335B2 (en) 2020-07-31 2022-12-20 University Of Iowa Research Foundation Compositions and methods for treating cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2914563A (en) * 1957-08-06 1959-11-24 Wm S Merrell Co Therapeutic composition
US5236899A (en) * 1987-11-16 1993-08-17 Merck & Co., Inc. 6-position cyclosporin a analogs as modifiers of cytotoxic drug resistance
US4990538A (en) * 1989-08-23 1991-02-05 Harris Adrian L Use of toremifene and its metabolites for the reversal of multidrug resistance of cancer cells against cytotoxic drugs
US5182293A (en) * 1989-11-13 1993-01-26 Merrell Dow Pharmaceuticals Inc. Treatment of multi-drug resistant tumors with pyridyloxazole-2-ones
ZA908852B (en) * 1989-11-13 1991-09-25 Merrell Dow Pharma Treatment of multi-drug resistant tumors with pyridyloxazole-2-ones

Also Published As

Publication number Publication date
GR3021811T3 (en) 1997-02-28
US5665780A (en) 1997-09-09
EP0624090A1 (en) 1994-11-17
EP0624090B1 (en) 1996-09-18
NO942918L (en) 1994-08-05
AU668910B2 (en) 1996-05-23
KR950700061A (en) 1995-01-16
JPH07503728A (en) 1995-04-20
TW226330B (en) 1994-07-11
ZA93690B (en) 1993-09-06
IL104599A (en) 1997-01-10
US5523304A (en) 1996-06-04
HU9402284D0 (en) 1994-10-28
DE69304895T2 (en) 1997-02-06
NZ246818A (en) 1997-07-27
NO942918D0 (en) 1994-08-05
ES2094525T3 (en) 1997-01-16
CA2129143C (en) 1997-05-06
ATE142879T1 (en) 1996-10-15
DK0624090T3 (en) 1996-11-11
WO1993015733A1 (en) 1993-08-19
CA2129143A1 (en) 1993-08-19
HUT75163A (en) 1997-04-28
MX9300578A (en) 1993-08-01
AU3440893A (en) 1993-09-03
IL104599A0 (en) 1993-06-10

Similar Documents

Publication Publication Date Title
DE69304895D1 (en) Elimination of multi-drug resistance by tetraarylethylenes
ITTO920976A1 (en) BIMODAL EMULSION AND RELATED METHOD OF PREPARATION.
ATE255906T1 (en) ANTIBODIES AGAINST CD40
IS2606B (en) Tumor associated with tumor necrosis factor
IL101925A0 (en) Inhibitors of cathepsin g and elastase for preventing connective tissue degradation
DE69003951T2 (en) MANUFACTURE OF MULTILAYER FILMS BY SPUTTERING.
DE3585728D1 (en) COMPOSITIONS OF UNSATURATED POLYESTER RESIN.
ATE256183T1 (en) NEW PROTEINS FROM PARASITIC WORMS
CA2152794A1 (en) Diarylalkyl Piperidines Useful as Multi-Drug Resistant Tumor Agents
DE69111277D1 (en) Accelerating setting of cement compositions in oil wells.
DE69200861T2 (en) Concentration of tert-butyl hydroperoxide.
ES2106183T3 (en) ANTI-POISON SERUM.
DE68901491D1 (en) METHOD TO PREVENT THE DISCOLORATION OF EMULSIONS AND EMULSION COMPOSITION RESISTANT TO DISCOLORATION.
DE69605624D1 (en) Sensitization of silver halide emulsions with precious metal complexes
DE68910343T2 (en) Purification of tertiary butanol.
DE68920675D1 (en) Graft copolymers, effective as additives for unsaturated polyester resins.
DE3887874D1 (en) Manufacture of customized integrated circuits.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee